CalciMedica (NASDAQ:CALC – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.03, FiscalAI reports.
CalciMedica Stock Performance
Shares of CALC traded up $0.10 during trading hours on Thursday, reaching $1.34. 11,450 shares of the company traded hands, compared to its average volume of 174,428. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The stock’s fifty day moving average is $1.57 and its 200 day moving average is $3.25. CalciMedica has a 1-year low of $1.00 and a 1-year high of $36.00. The stock has a market cap of $9.15 million, a P/E ratio of -0.30 and a beta of 0.84.
Analysts Set New Price Targets
CALC has been the topic of a number of research analyst reports. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. Finally, Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CalciMedica currently has an average rating of “Hold” and a consensus price target of $50.00.
Get Our Latest Analysis on CALC
CalciMedica Company Profile
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.
Featured Stories
- Five stocks we like better than CalciMedica
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
- Tesla’s Plan to End Cybertruck Reveals Its Real Priorities
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
